HIV: Treating Patients with Viral Mutations

Opinion
Video

Sorana Segal-Maurer, MD, offers clinical insights on treating patients with HIV who have viral mutations, including M184V, highlighting guideline recommendations.

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following questions:

  • Patients with viral mutations, including M184V, require a different and more tailored therapeutic approach to manage their disease.
    • Can you share your treatment approach for a patient with a viral mutation, such as M184V?
    • What are the current treatment guideline recommendation on this?
Recent Videos
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
A panel of 5 experts on C. difficile infections
© 2024 MJH Life Sciences

All rights reserved.